Axsome Therapeutics Q1 Earnings Call Highlights

3 days ago 5

MarketBeat

Mon, May 4, 2026 astatine 9:38 AM CDT 9 min read

Axsome Therapeutics logo

Key Points

Total Q1 gross for Axsome’s 3 marketed products was $191 million, up 57% YoY—led by Auvelity nett merchandise gross of $153.2M (+59%) and Sunosi $33.9M (+34%)—with a nett nonaccomplishment of $64.5M and $305M successful cash, which absorption says funds operations into cash‑flow positivity nether the existent plan.
Axsome won FDA approval for Auvelity for agitation associated with Alzheimer’s illness and is preparing a commercialized June launch, expanding the salesforce to astir 630 reps and achieving astir 86% payer sum crossed channels.
Management raised Auvelity’s highest income outlook to astatine slightest $8 billion and emphasized pipeline momentum, including an NDA filing for AXS‑12 (narcolepsy/cataplexy) and aggregate planned oregon ongoing signifier III programs for AXS‑05, solriamfetol, AXS‑14 and AXS‑20.
Interested successful Axsome Therapeutics, Inc.? Here are 5 stocks we similar better.

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Axsome Therapeutics (NASDAQ:AXSM) reported first-quarter 2026 results highlighting beardown year-over-year gross growth, a large caller FDA support for Auvelity, and continued advancement crossed its neuroscience pipeline. Management besides elaborate commercialized investments to enactment an upcoming motorboat successful Alzheimer’s illness agitation and provided an updated semipermanent income outlook for the Auvelity franchise.

Q1 gross grew 57% arsenic Auvelity and Sunosi drove results

Chief Executive Officer Dr. Herriot Tabuteau said the institution delivered “strong year-over-year maturation and execution crossed the business,” citing contributions from its 3 marketed products and pipeline progress. Total gross for the 3 marketed products was $191 million, up 57% versus the archetypal 4th of 2025, driven chiefly by Auvelity and Sunosi, with publication from Symbravo.

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

5 aesculapian stocks increasing net by triple digits

Chief Financial Officer Nick Pizzie reported quarterly nett merchandise gross of $153.2 million for Auvelity, up 59% year-over-year. Sunosi nett merchandise gross was $33.9 million, up 34%, including $32.6 million successful nett merchandise income and $1.3 million successful royalty gross successful out-licensed territories. Symbravo recorded $4.1 million successful nett sales.

Pizzie noted gross-to-net discounts for Auvelity and Sunosi were “in the debased to mid-50s range,” and helium said the institution anticipates betterment done the twelvemonth accordant with anterior trends. Symbravo’s gross-to-net was “in the precocious 70% range,” which helium said is expected to stay elevated adjacent word arsenic entree evolves and consciousness builds.

Read Entire Article